These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2405 related items for PubMed ID: 18035186

  • 1. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 2. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR.
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [Abstract] [Full Text] [Related]

  • 3. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 4. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 5. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH, Chen JJ.
    Clin Neuropharmacol; 2007 Oct; 30(3):150-68. PubMed ID: 17545750
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E, Stern MB.
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [Abstract] [Full Text] [Related]

  • 15. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW.
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ, Wilkinson JR.
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [Abstract] [Full Text] [Related]

  • 18. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J, Rodríguez-Oroz MC.
    Rev Neurol; 2013 Jan 01; 56(1):25-34. PubMed ID: 23250679
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, TEMPO Open-label Study Group.
    Mov Disord; 2009 Mar 15; 24(4):564-73. PubMed ID: 19086083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 121.